TY - JOUR T1 - Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. JF - The Journal of Rheumatology JO - J Rheumatol SP - 740 LP - 743 VL - 32 IS - 4 AU - Adam Mor AU - Clifton Bingham, 3rd AU - Laura Barisoni AU - Eileen Lydon AU - H Michael Belmont Y1 - 2005/04/01 UR - http://www.jrheum.org/content/32/4/740.abstract N2 - Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA. ER -